Sign in
Join
Discovery/Preclinical
In vitro
In vivo
Newer Targets
Clinical
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Phase IV
Recall
Commercial
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Sign in / Join
Contact
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Discovery/Preclinical
All
In vitro
In vivo
Newer Targets
Newer Targets
Novel discovery in gene therapy to treat kidney diseases …
Newer Targets
Stanford researchers program cancer-fighting cells to resist exhaustion, attack solid tumors…
Newer Targets
Dyno Therapeutics Announces Research Published in Science Enabling Artificial Intelligence Approach…
Newer Targets
Hepion Pharmaceuticals’ CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver…
Clinical
All
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Phase IV
Recall
FDA/EMA/Drug Designation
FDA Committee Votes 6-6 on Durect’s Non-Opioid Pain Drug
Approval
Novo Nordisk’s Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes…
FDA/EMA/Drug Designation
FDA advisory panel split on whether to approve Durect’s Posimir for…
Approval
Breast cancer patients to have further NICE-approved drug combination option on…
Commercial
All
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Deals
Seneca Biopharma Surges Near 113% After Comments on Seeking Partnership for…
Deals
TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy…
Commercial
US judge hacks $8-billion damages verdict against Johnson & Johnson in…
Deals
JPM Day 3: High Prices in San Francisco Are a Problem,…
Home
Clinical
FDA/EMA/Drug Designation
FDA/EMA/Drug Designation
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
FDA/EMA/Drug Designation
FDA Committee Votes 6-6 on Durect’s Non-Opioid Pain Drug
Biospace News
-
January 17, 2020
FDA/EMA/Drug Designation
FDA advisory panel split on whether to approve Durect’s Posimir for post-surgical analgesia
FDA/EMA/Drug Designation
U.S. FDA panel split over approval of Durect’s non-opioid painkiller ...
FDA/EMA/Drug Designation
DURECT Corporation Trading Halted Today; FDA Advisory Committee to Discuss POSIMIR (bupivacaine extended-release solution) for Post-Surgical Analgesia
FDA/EMA/Drug Designation
Intellipharmaceutics’ shares dive after FDA panel rejects opioid pain drug Aximris XR
FDA/EMA/Drug Designation
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Biospace News
-
January 15, 2020
0
FDA/EMA/Drug Designation
Janssen Seeks Expanded Use of SPRAVATO (Esketamine) Nasal Spray in Europe...
Firstwordpharma News
-
January 15, 2020
0
FDA/EMA/Drug Designation
FDA panel rejects Nektar’s opioid analgesic NKTR-181 citing safety concerns, lack...
Firstwordpharma News
-
January 14, 2020
0
FDA/EMA/Drug Designation
Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement...
Firstwordpharma News
-
January 10, 2020
0
FDA/EMA/Drug Designation
FDA to Pull Nearly 250 ANDAs, Continues to Revamp OND
Biospace News
-
January 10, 2020
0
1
2
3
...
35
Page 1 of 35
- Advertisement -
MOST POPULAR
Qilu Pharmaceutical Expanding Biopharmaceutical Production Capacity with ABEC Bioreactor Systems
May 29, 2019
MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to...
January 17, 2019
Gilead and Novo Nordisk Team up to Tackle NASH
April 12, 2019
Tumour Mutational Burden Predicts Response to Immunotherapy in Patients With Advanced...
April 16, 2019
Load more
HOT NEWS
Phase II
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare...
Commercial
AmerisourceBergen Reports Fiscal 2019 First Quarter Results
NDA
Urovant Sciences Announces Submission of New Drug Application for Vibegron for...
Phase I
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar,...
